European Commission Revokes TAVNEOS Marketing Authorization in EU

The European Commission has revoked the marketing authorization for TAVNEOS (avacopan) in the EU and EEA, a treatment for severe ANCA-associated vasculitis. This decision follows an EMA recommendation due to concerns over data handling in the pivotal Phase 3 ADVOCATE trial. Patients currently on TAVNEOS are advised to discuss alternative treatment plans with their physicians, impacting treatment options for this condition.